Cargando…
Fondaparinux: A cornerstone drug in acute coronary syndromes
In acute coronary syndrome (ACS), the use of anticoagulants in conjunction with antiplatelet agents in the acute phase has resulted in reduced ischemic events and is more effective than either class of drug used alone. Though parenteral anticoagulation is essential at the time of diagnosis, a balanc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788176/ https://www.ncbi.nlm.nih.gov/pubmed/35126871 http://dx.doi.org/10.4330/wjc.v14.i1.40 |
_version_ | 1784639502776532992 |
---|---|
author | Khan, Mohammed Yunus Ponde, Chandrashekhar K Kumar, Viveka Gaurav, Kumar |
author_facet | Khan, Mohammed Yunus Ponde, Chandrashekhar K Kumar, Viveka Gaurav, Kumar |
author_sort | Khan, Mohammed Yunus |
collection | PubMed |
description | In acute coronary syndrome (ACS), the use of anticoagulants in conjunction with antiplatelet agents in the acute phase has resulted in reduced ischemic events and is more effective than either class of drug used alone. Though parenteral anticoagulation is essential at the time of diagnosis, a balance must be made between ischemic benefit and the increased risk of bleeding when prescribing anticoagulants. Adverse events associated with anticoagulants, such as heparin-induced thrombocytopenia, bleeding problems, and the need for close monitoring of anticoagulant activity, have contributed to finding agents that reduce these limitations. Studies like the Organization to Assess Strategies in Ischemic Syndromes 5 and 6 and their meta-analysis have proven the efficacy of Fondaparinux over the entire ACS spectrum. The convenience of administration (once daily), lack of monitoring, reduction in mortality, and better safety profile make Fondaparinux a simple and effective anti-coagulant for the management of ACS. |
format | Online Article Text |
id | pubmed-8788176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-87881762022-02-03 Fondaparinux: A cornerstone drug in acute coronary syndromes Khan, Mohammed Yunus Ponde, Chandrashekhar K Kumar, Viveka Gaurav, Kumar World J Cardiol Minireviews In acute coronary syndrome (ACS), the use of anticoagulants in conjunction with antiplatelet agents in the acute phase has resulted in reduced ischemic events and is more effective than either class of drug used alone. Though parenteral anticoagulation is essential at the time of diagnosis, a balance must be made between ischemic benefit and the increased risk of bleeding when prescribing anticoagulants. Adverse events associated with anticoagulants, such as heparin-induced thrombocytopenia, bleeding problems, and the need for close monitoring of anticoagulant activity, have contributed to finding agents that reduce these limitations. Studies like the Organization to Assess Strategies in Ischemic Syndromes 5 and 6 and their meta-analysis have proven the efficacy of Fondaparinux over the entire ACS spectrum. The convenience of administration (once daily), lack of monitoring, reduction in mortality, and better safety profile make Fondaparinux a simple and effective anti-coagulant for the management of ACS. Baishideng Publishing Group Inc 2022-01-26 2022-01-26 /pmc/articles/PMC8788176/ /pubmed/35126871 http://dx.doi.org/10.4330/wjc.v14.i1.40 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Khan, Mohammed Yunus Ponde, Chandrashekhar K Kumar, Viveka Gaurav, Kumar Fondaparinux: A cornerstone drug in acute coronary syndromes |
title | Fondaparinux: A cornerstone drug in acute coronary syndromes |
title_full | Fondaparinux: A cornerstone drug in acute coronary syndromes |
title_fullStr | Fondaparinux: A cornerstone drug in acute coronary syndromes |
title_full_unstemmed | Fondaparinux: A cornerstone drug in acute coronary syndromes |
title_short | Fondaparinux: A cornerstone drug in acute coronary syndromes |
title_sort | fondaparinux: a cornerstone drug in acute coronary syndromes |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788176/ https://www.ncbi.nlm.nih.gov/pubmed/35126871 http://dx.doi.org/10.4330/wjc.v14.i1.40 |
work_keys_str_mv | AT khanmohammedyunus fondaparinuxacornerstonedruginacutecoronarysyndromes AT pondechandrashekhark fondaparinuxacornerstonedruginacutecoronarysyndromes AT kumarviveka fondaparinuxacornerstonedruginacutecoronarysyndromes AT gauravkumar fondaparinuxacornerstonedruginacutecoronarysyndromes |